Over the years, Pharco has grown into a global pharmaceutical company with a presence across multiple regions. We continue to expand access to essential medicines while supporting healthcare systems and improving patient outcomes worldwide.
Pharco delivers medicines across global pharmaceutical markets through strong partnerships with healthcare providers and distribution networks. With a focus on access to essential medicines, we support patient care and ensure consistent supply across regions through our international pharmaceutical distribution and export operations
Pharco contributed to hepatitis C elimination efforts by expanding treatment access through national programs, working closely with healthcare authorities to reach millions of patients and supporting global health initiatives.
Through collaboration with public health partners, Pharco improved access to bilharzia treatment and supported national control programs addressing neglected tropical diseases.
Egypt's medical tourism initiative offers international Hepatitis C patients fast, affordable treatment with no waiting time, alongside a five-star stay and the chance to experience Egypt's historic landmarks during recovery. Program ambassadors include Lionel Messi, Dani Alves, Ahmed Hossam (Mido) and Mohamed Hamaki.
Pharco in the Media
Speaking to CNN's Marketplace Africa, Pharco Corporation's Chairman sets out how Egypt turned an affordable Hepatitis C cure into a national elimination programme, and what that model means for access to medicine across Africa and the Middle East.
Watch the InterviewPharco's commitment to quality and compliance has earned recognition from the world's most respected regulatory and health authorities.
Stay updated with Pharco's latest developments, research progress, and partnerships shaping the future of healthcare.
Pharco Pharmaceuticals, a leading pharmaceutical company, and Alameda Healthcare Group, a prominent healthcare provider, have signed a strategic Memorandum of Understanding (MoU) to collaborate on patient support, disease awareness, and scientific and medical education, with a focus on chronic disease care.
Adwaya Pharco International, Pharco’s arm in Saudi Arabia, signed an S&L agreement with Shilpa Pharma Lifesciences during CPHI Milan 2026. The agreement provides access to an innovative technology intended to strengthen the company’s capabilities and support its continued growth in the Saudi market.
Pharco Pharmaceuticals signed a Memorandum of Understanding with Baheya Hospitals to strengthen cooperation in oncology care and support the development of healthcare services. The signing took place in the presence of Dr. Sherine Helmy, Chairman and CEO of Pharco Pharmaceuticals.
